JP2005237328A5 - - Google Patents

Download PDF

Info

Publication number
JP2005237328A5
JP2005237328A5 JP2004053795A JP2004053795A JP2005237328A5 JP 2005237328 A5 JP2005237328 A5 JP 2005237328A5 JP 2004053795 A JP2004053795 A JP 2004053795A JP 2004053795 A JP2004053795 A JP 2004053795A JP 2005237328 A5 JP2005237328 A5 JP 2005237328A5
Authority
JP
Japan
Prior art keywords
base sequence
immunostimulatory oligonucleotide
immunomodulator
seq
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004053795A
Other languages
English (en)
Japanese (ja)
Other versions
JP3976742B2 (ja
JP2005237328A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2004053795A priority Critical patent/JP3976742B2/ja
Priority claimed from JP2004053795A external-priority patent/JP3976742B2/ja
Priority to PCT/JP2005/003693 priority patent/WO2005083076A1/ja
Priority to US10/590,761 priority patent/US7718623B2/en
Publication of JP2005237328A publication Critical patent/JP2005237328A/ja
Publication of JP2005237328A5 publication Critical patent/JP2005237328A5/ja
Application granted granted Critical
Publication of JP3976742B2 publication Critical patent/JP3976742B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2004053795A 2004-02-27 2004-02-27 インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド Expired - Lifetime JP3976742B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2004053795A JP3976742B2 (ja) 2004-02-27 2004-02-27 インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
PCT/JP2005/003693 WO2005083076A1 (ja) 2004-02-27 2005-02-25 インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
US10/590,761 US7718623B2 (en) 2004-02-27 2005-02-25 Immunostimulatory oligonucleotide that induces interferon alpha

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004053795A JP3976742B2 (ja) 2004-02-27 2004-02-27 インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド

Publications (3)

Publication Number Publication Date
JP2005237328A JP2005237328A (ja) 2005-09-08
JP2005237328A5 true JP2005237328A5 (enExample) 2006-10-12
JP3976742B2 JP3976742B2 (ja) 2007-09-19

Family

ID=34908763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004053795A Expired - Lifetime JP3976742B2 (ja) 2004-02-27 2004-02-27 インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド

Country Status (3)

Country Link
US (1) US7718623B2 (enExample)
JP (1) JP3976742B2 (enExample)
WO (1) WO2005083076A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4817599B2 (ja) * 2003-12-25 2011-11-16 独立行政法人科学技術振興機構 免疫活性増強剤とこれを用いた免疫活性の増強方法
DK2034015T3 (da) * 2006-05-31 2012-10-15 Toray Industries Immunstimulerende oligonucleotid og farmaceutisk anvendelse heraf
WO2008133358A1 (en) * 2007-04-27 2008-11-06 Hyunjin Yang Scaffolds increased specific gravity for cell culture and method for manufacturing thereof
WO2009069447A1 (ja) * 2007-11-28 2009-06-04 Toray Industries, Inc. インフルエンザワクチン用のアジュバント及びインフルエンザワクチン
WO2009069448A1 (ja) * 2007-11-28 2009-06-04 Toray Industries, Inc. 日本脳炎ワクチン用のアジュバント及び日本脳炎ワクチン
JP5359883B2 (ja) * 2007-11-28 2013-12-04 東レ株式会社 肝炎の治療剤又は予防剤
BRPI0923225A2 (pt) 2008-12-02 2016-10-04 Chiralgen Ltd metodo para sintese de acidos nucleicos modificados no atomo de fosforo
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
GB201021867D0 (en) * 2010-12-23 2011-02-02 Mologen Ag Non-coding immunomodulatory DNA construct
JP5906019B2 (ja) * 2011-03-31 2016-04-20 国立大学法人福井大学 免疫刺激g9.1の抗結核ブースターワクチン創出への応用
CN107365339A (zh) 2011-07-19 2017-11-21 波涛生命科学有限公司 合成官能化核酸的方法
US12268718B2 (en) 2012-01-16 2025-04-08 Labyrinth Holdings Llc Control of cellular redox levels
SG10202013014RA (en) 2012-01-16 2021-02-25 Mckenna Elizabeth Compositions and Methods for the Treatment of Hepatic Diseases and Disorders
US20140086849A1 (en) * 2012-09-21 2014-03-27 Elizabeth McKenna Naturally-Occurring CpG Oligonucleotide Compositions and Therapeutic Applications Thereof
AR091569A1 (es) * 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
DK2872147T3 (da) 2012-07-13 2023-02-20 Wave Life Sciences Ltd Fremgangsmåde til fremstilling af kirale oligonukleotider
SG11201500243WA (en) * 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
EP3094728B1 (en) 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chiral design
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
KR20240082367A (ko) * 2021-09-23 2024-06-10 아르네이 사이언시스 엘엘씨 치료학적 물질로서 고리형 구조의 올리고뉴클레오티드

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0468520A3 (en) * 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
WO1998055609A1 (en) 1997-06-06 1998-12-10 The Regents Of The University Of California Inhibitors of dna immunostimulatory sequence activity
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
IL148844A0 (en) * 1999-09-27 2002-09-12 Coley Pharm Group Inc Methods related to immunostimulatory nucleic acid-induced interferon
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
WO2002002172A1 (en) * 2000-06-30 2002-01-10 Univ Jefferson Dna palindrome - oligoguanylic acid compositions and uses thereof
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
EP1425040A2 (en) 2001-09-14 2004-06-09 Cytos Biotechnology AG In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
ATE489969T1 (de) 2002-06-20 2010-12-15 Cytos Biotechnology Ag Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung

Similar Documents

Publication Publication Date Title
JP2003531157A5 (enExample)
JP2006512300A5 (enExample)
JP2007522094A5 (enExample)
JP2006516528A5 (enExample)
JP2006141398A5 (enExample)
JP2007302683A5 (enExample)
EP1728863A3 (en) C-class oligonucleotide analogs with enhanced immunostimulatory potency
JP2003530473A5 (enExample)
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
NO20031646D0 (no) Ajuvantsammensetning omfattende et immunostimulatorisk oligonukleotid og entokol
JP2001131087A5 (enExample)
JP2005532372A5 (enExample)
MXPA03011972A (es) Arilaminas para tratamiento de condiciones asociadas con gsk-3.
JP2007515393A5 (enExample)
JP2007505773A5 (enExample)
SE0102440D0 (sv) New compound
JP2020117504A5 (enExample)
DE502004005560D1 (de) Pharmazeutische formulierungen enthaltend hochreine basen von 3,3-diphenylpropylaminmonoestern
JP2005509503A5 (enExample)
JP2004532624A5 (enExample)
JP2008503221A5 (enExample)
JP2006512078A5 (enExample)
WO2002053149A3 (de) Arzneimittel enthaltend ein polyamin als wirksubstanz
JP2002277470A5 (enExample)
JP2011514167A5 (enExample)